V-Bio Ventures


V-Bio Ventures is an independent venture capital firm specialized in building and financing young, innovative life science companies. V-Bio Ventures was established in 2015 and works closely with Belgium-based VIB, one of the world’s premier life science institutes. The fund invests throughout Europe in start-up and early-stage companies with high growth potential focusing on technologies that provide transformational improvements in the biopharmaceutical, pharmaceutical, diagnostics and agricultural sectors.



PMV is a do and dare company that shapes the economic future of Flanders. PMV finances promising companies from the very start to growth and internationalization. PMV offers tailor-made financial solutions for every entrepreneur with a solid business plan and a strong management team, by providing venture capital, loans and guarantees. An experienced and highly motivated team of 125 professionals endeavors every day to achieve the goal of creating prosperity and well-being in Flanders. PMV has a portfolio of about € 1.3 billion in assets under management.  More info about PMV can be found on .

Biotech Fund Flanders is a PMV managed venture fund focused on investments in life science projects.



Advent France Biotechnology


Advent France Biotechnology is a French Life Sciences Venture Capital firm dedicated to seeding healthcare’s step forward. We work with leading research institutions and well-established technology transfer offices, with a strong network of scientific and medical partners, exploring new territories to source breakthrough medical discoveries and drive inventive Life Sciences start-ups to success.


We embrace French and Benelux Life Sciences’ dynamic of innovation. These countries harbor a vibrant environment for medical and scientific investigation, with some of the most leading-edge academic and research centers. Advent France Biotechnology seizes the opportunity to highlight their undervalued research programs and assets and participate in structuring the biotechnology ecosystem. Advent France Biotechnology is supported by Advent Life Sciences, one of Europe’s leading venture teams investing in Life Sciences businesses, giving direct access to their team of 15 investment professionals. Advent France Biotechnology applies the investment methodology of Advent Life Sciences that has proven to be highly successful in seeding, creating and supporting early stage Life Sciences projects in the UK and the US for 4 decades. Advent France Biotechnology was founded in 2015 and is AMF regulated since 2016.





The Gemma Frisius Fund (GFF) is a seed capital fund, established in 1997 as a joint venture between KU Leuven, KBC Private Equity and BNP Paribas Fortis Private Equity. The fund combines the research and technology transfer expertise of the university with the financial and investment expertise of the two financial partners. GFF provides seed capital in the early development stages of innovative, research-based spin-off companies originating from all technology domains and provides support in their further growth process.  




VIB is an excellence-based entrepreneurial research institute in life sciences that focuses on translating basic scientific results into pharmaceutical, agricultural and industrial applications. VIB’s Innovation & Business team currently has a portfolio of 230 patent families. This team conducts about 120 partnering agreements with innovative companies each year. VIB is also firmly-rooted in a long-standing tradition of setting up start-up companies. Since its foundation in 1996, VIB has created more than 20 start-up companies. VIB is funded by the Flemish government and works in close partnership with five Flemish universities – Ghent University, KU Leuven, University of Antwerp, Vrije Universiteit Brussel and Hasselt University.